Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...

Please provide your email address to receive an email when new articles are posted on . The risk for thyroid cancer within the first year of follow-up was higher with GLP-1 therapy vs. other ...

GLP-1 receptor agonists conferred greater HbA1c reductions in older adults than younger adults. Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors.